Compare KO & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KO | MRK |
|---|---|---|
| Founded | 1886 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.4B | 260.2B |
| IPO Year | 1919 | N/A |
| Metric | KO | MRK |
|---|---|---|
| Price | $70.58 | $100.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 15 |
| Target Price | $78.15 | ★ $109.13 |
| AVG Volume (30 Days) | ★ 17.7M | 15.8M |
| Earning Date | 10-21-2025 | 10-30-2025 |
| Dividend Yield | 2.89% | ★ 3.39% |
| EPS Growth | 25.34 | ★ 58.08 |
| EPS | 3.02 | ★ 7.56 |
| Revenue | $47,663,000,000.00 | ★ $64,235,000,000.00 |
| Revenue This Year | $5.66 | $1.97 |
| Revenue Next Year | $5.00 | $4.96 |
| P/E Ratio | $23.35 | ★ $13.27 |
| Revenue Growth | ★ 2.80 | 1.68 |
| 52 Week Low | $60.62 | $73.31 |
| 52 Week High | $74.38 | $105.84 |
| Indicator | KO | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 50.32 | 59.78 |
| Support Level | $68.79 | $96.06 |
| Resistance Level | $70.69 | $99.85 |
| Average True Range (ATR) | 1.03 | 2.46 |
| MACD | -0.31 | -0.70 |
| Stochastic Oscillator | 40.20 | 43.03 |
Founded in 1886, Atlanta-headquartered Coca-Cola is the world's largest nonalcoholic beverage company, with a strong portfolio of 200 brands covering key categories including carbonated soft drinks, water, sports, energy, juice, and coffee. Together with bottlers and distribution partners, the company sells finished beverage products bearing Coca-Cola and licensed brands through retailers and food-service locations in more than 200 countries and regions globally. Coca-Cola generates around two thirds of its total revenue overseas, with a significant portion from emerging economies in Latin America and Asia-Pacific.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).